All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
45th Annual Meeting of the EBMT, 24–27 March 2019, Frankfurt, DE
Dana-Farber Cancer Institute, Boston, US
Interview Topic (English): Treatment of relapsed/refractory multiple myeloma
Paul Richardson | EBMT 2019 | Treatment of relapsed/refractory multiple myeloma
Katja Weisel | EHA 2018 | Turning the tide after relapse: managing relapsed MM
Katja Weisel outlined some of the key clinical trials for relapsed and refractory patients that have led to several safe and effective new combination regimens
EHA 22nd Congress: Navigating the complex waters in RRMM
The era of novel agents has hugely improved the prognosis for RRMM patients.
Subscribe to get the best content related to multiple myeloma delivered to your inbox